As of now, that's about the right PV for SGEN and what it would take to get it done. However from the buyer perspective it would be pretty difficult to make such offer (i.e 200% mark up) and from my perspective as a shareholder that would be the lowest price that I'd sell it for now. If half of the ongoing trials in all 3 phases yield results comparable to those seen with ADCETRIS the low end share price in 3-5 years would be $200.
European approval, increased label usage, plenty of cash and addition of new collaborations and partnerships should be on the horizon. Any new big pharma players and we breakthrough the $30 barrier.
Pharma is looking for alternatives to patent cliffs and are recognizing the platforms using ADCs. FDA is getting more understanding of the process and legislation allowing for expedited approval can only help. Sweet spot to be in.
Why end the revenue and growth stream before maturing and thereby selling out early. SGEN is a company where the investment continues to be one to increase shares at this time.